Donald E. Bobo, Jr. Sells 6,725 Shares of Edwards Lifesciences Co. (NYSE:EW) Stock

Edwards Lifesciences Co. (NYSE:EWGet Rating) VP Donald E. Bobo, Jr. sold 6,725 shares of the stock in a transaction dated Thursday, September 8th. The shares were sold at an average price of $90.94, for a total value of $611,571.50. Following the completion of the transaction, the vice president now owns 62,561 shares in the company, valued at approximately $5,689,297.34. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $97.25 on Friday. Edwards Lifesciences Co. has a 12-month low of $85.58 and a 12-month high of $131.73. The company has a market cap of $60.29 billion, a price-to-earnings ratio of 42.10, a price-to-earnings-growth ratio of 2.81 and a beta of 1.14. The stock has a 50 day simple moving average of $98.52 and a 200-day simple moving average of $103.02. The company has a current ratio of 3.37, a quick ratio of 2.60 and a debt-to-equity ratio of 0.10.

Edwards Lifesciences (NYSE:EWGet Rating) last released its quarterly earnings data on Thursday, July 28th. The medical research company reported $0.63 earnings per share for the quarter, missing the consensus estimate of $0.64 by ($0.01). Edwards Lifesciences had a net margin of 27.18% and a return on equity of 24.77%. The firm had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.40 billion. During the same period in the previous year, the business earned $0.64 earnings per share. The business’s revenue for the quarter was down .2% on a year-over-year basis. On average, equities analysts forecast that Edwards Lifesciences Co. will post 2.51 EPS for the current year.

Analyst Ratings Changes

EW has been the topic of a number of recent analyst reports. Cowen dropped their price objective on Edwards Lifesciences from $140.00 to $125.00 in a report on Monday, July 11th. Canaccord Genuity Group cut Edwards Lifesciences from a “buy” rating to a “hold” rating and decreased their target price for the company from $115.00 to $106.00 in a research report on Friday, July 29th. Stifel Nicolaus decreased their target price on Edwards Lifesciences from $128.00 to $115.00 in a research report on Monday, July 18th. Canaccord Genuity Group cut Edwards Lifesciences from a “buy” rating to a “hold” rating and decreased their target price for the company from $115.00 to $106.00 in a research report on Friday, July 29th. Finally, Morgan Stanley decreased their target price on Edwards Lifesciences from $136.00 to $119.00 and set an “overweight” rating for the company in a research report on Friday, July 15th. Three investment analysts have rated the stock with a hold rating and nineteen have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $126.19.

Hedge Funds Weigh In On Edwards Lifesciences

Hedge funds have recently bought and sold shares of the company. American National Bank increased its stake in Edwards Lifesciences by 99.1% in the 1st quarter. American National Bank now owns 233 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 116 shares in the last quarter. Core Alternative Capital increased its position in Edwards Lifesciences by 513.2% during the first quarter. Core Alternative Capital now owns 233 shares of the medical research company’s stock worth $27,000 after buying an additional 195 shares in the last quarter. Rinkey Investments purchased a new position in Edwards Lifesciences during the fourth quarter worth $29,000. JJJ Advisors Inc. increased its position in Edwards Lifesciences by 79.1% during the first quarter. JJJ Advisors Inc. now owns 283 shares of the medical research company’s stock worth $33,000 after buying an additional 125 shares in the last quarter. Finally, Crewe Advisors LLC purchased a new position in Edwards Lifesciences during the second quarter worth $28,000. 81.33% of the stock is owned by hedge funds and other institutional investors.

About Edwards Lifesciences

(Get Rating)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Featured Articles

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.